Information on this page is provided as a guide and may change. Please verify details directly with the treatment center or other appropriate source before making care decisions.

Institution Logo

Duke Cancer Institute

Center for Prostate and Urologic Cancers

Primary Address

20 Duke Medicine Circle
Durham, NC, 27710

Satellite Locations

Duke Urology Clinic- Clinic 1G

40 Duke Medicine Cir Durham, NC 27710

Duke Pediatric Urology South Durham

234 Crooked Creek Pkwy Durham, NC 27713

Duke Urology of Raleigh

3480 Wake Forest Rd, Suite 506 Raleigh, NC 27609

Key Contacts

Director of Genitourinary Oncology:
Dr. Daniel George – Professor
Medical Oncology Lead:
Dr. Michael Harrison – Associate Professor
Urologic Surgery Lead:
Dr. Michael Abern – Associate Professor
Radiation Oncology Lead:
Dr. Paul Koffer – Assistant Professor
Patient Navigator & Appointments:
Call (855) 855-6484
Clinical Trials Contact:
[email protected]
(919) 681-5698

Volume

Metrics reflect this center’s demonstrated experience across key areas of kidney cancer care.

Kidney Cancer Surgery Volume

High

Clear Cell Kidney Cancer Diagnosis Volume

Medium

Non–Clear Cell Kidney Cancer Diagnosis Volume

High

Clinical Trial Participation Volume

High

Radiation & Ablation Procedure Volume

Very High

About these ratings

Volume and expertise levels are determined using standardized thresholds established by the Kidney Cancer Association and updated annually. Metrics are based on available data and may not reflect the full scope of a center’s capabilities or activity. These metrics are intended to help patients identify centers with demonstrated experience in kidney cancer care.

Types of Services Offered

Clinical Trials End of Life Services Genetic Counseling Infusion Center Integrative Oncology Molecular Testing Multidisciplinary Clinic Oncology Urgent Care Clinic Palliative & Supportive Care Patient Case Discussions / Tumor Boards Precision Medicine Survivorship Clinics Interventional Radiology Medical Oncology Pain Management Palliative Care Pathology Radiation Oncology Radiology Urologic Surgery

Kidney Cancer Types & Expertise

Chromophobe RCC Clear Cell RCC Collecting Duct RCC FH-deficient RCC Papillary RCC Renal Medullary Carcinoma Sarcomatoid Translocation RCC Tuberous Sclerosis–associated RCC Unclassified RCC VHL-associated RCC Bilateral Kidney Tumors Complex Recurrent Cases Cystic Renal Tumors Hereditary Syndromes Kidney Transplant Recipients Pregnancy Solitary Kidney Young Adult (age 18-50)

Special Programs, Recognitions & Outcomes

American College of Surgeons Accredited Cancer Program Government-Funded Research Member of Kidney Cancer Consortium NCI Designated Cancer Center

Consortium Member

Alliance for Clinical Trials in Oncology, NRG Oncology, Kidney Cancer Research Consortium (KCRC)

Research Programs

Clinical Multi-Institutional Collaboration Population-Based Research Lab Translational

Multi-Institutional Collaborations

Prosthetic Urology Multi-Institutional Partnerships (PUMP)
FORWARD Urology Centers
NIH-Related Training & Research Networks (NC KUH TRIO)
Industry & Multi-Center Clinical Trials

Patient Resources & Support Services

Art Therapy Fertility Preservation Counseling Financial Navigators Interpreter Services Lodging / Long-Term Housing Music Therapy Nurse Navigators Nutrition Services / Dietician Occupational Therapy On-site Dispensing / Pharmacy Parking Assistance (valet or concierge) Patient Navigators Peer Support Options Physical Therapy Psychiatrists / Psychologists Social Workers / Counselors Transportation Service Wellness Center

Insurance Carriers

Accepted

  • Aetna
  • Blue Cross Blue Shield of North Carolina
  • CIGNA Healthcare of NC
  • Duke basic and Duke select plans
  • Gateway Health Alliance
  • Humana PPO plans
  • MedCost
  • Optima Health
  • Ambetter of NC
  • Medicare
  • Medicaid
  • TRICARE
  • VA-CCN
  • CHAMPVA
  • Trillium Community Health Plan
  • Wellcare
  • Western Health Advantage

Insurance information is provided as a guide and may change. Participation can vary by plan, location, and individual coverage. Please contact the treatment center and your insurance provider directly to confirm that your specific insurance plan is currently accepted and to understand any applicable coverage requirements or costs.

Open Clinical Trials

STRIKE

Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer (STRIKE)

SAMURAI

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial (SAMURAI)

STELLAR-002

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors (STELLAR-002)

Calico

Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors

PEAK-1

Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma